To assess the impact of ACT on tumor growth, 1x106, 2x106 or 5x106 OT-I CD8+ T cells were injected intravenously in the mice tail vein, 11 days after subcutaneous tumor engraftment. This evidence concerns the gene CD8A and neoplasm.